Context: Endothelial microRNA 126 (miR-126) attenuates the development of atherosclerosis (AS). However, there is no evidence showing the role of miR-126 in estrogen's antiatherogenic effects.
receiving ERT early after menopause had significantly beneficial cardiovascular outcomes (3) . Therefore, the cardiovascular effects and the underlying mechanisms of estrogen are worthy of further investigation.
Estrogen retards atherogenesis in numerous in vivo and in vitro experiments. Mechanistically, 17b-estradiol (E2) improves lipid profile, induces vasorelaxation by increasing nitric oxide and hydrogen sulfide release (4, 5) , accelerates endothelial repair by promoting endothelial proliferation and migration (6) , inhibits vascular smooth muscle cell proliferation and migration (7) , and alleviates vascular inflammatory response by modulating functions of immune cells (8) . Of these, the direct effects of E2 on vascular endothelial cells appear to be critical because endothelial dysfunction is the initial step of atherosclerosis (AS) (9) . However, the molecular mechanisms of estrogen actions on vascular endothelial cells are not fully elucidated.
MicroRNAs (miRNAs) are short nucleotides and noncoding RNA molecules that base pair with the 3 0 untranslated region of target messenger RNAs (mRNAs) and block their translation. Recently, miRNAs have been efficiently studied as 1 of the important candidates for involvement in vascular endothelial functions and AS (10) . For instance, miRNA 126 (miR-126) maintains a proliferative reserve in vascular endothelial cells and prevents atherosclerotic lesion formation (11) . miR-26 prevents endothelial cell apoptosis and retards atherogenesis (12) . Thus, the identification and the respective targets of miRNAs may provide novel molecular insight and new therapeutic strategies to treat AS.
Estrogen serves as a powerful regulator of miRNAs (13) . For example, E2 promotes cell migration and invasion in MCF-7 breast cancer cells via downregulation of miR-124 (14) . However, these studies were performed exclusively in reproductive organs including the mammary gland and uterus. To our knowledge, there is no evidence at present addressing the functions of estrogenregulated miRNAs and their implications in AS.
Recent evidence shows that miR-126-3p, the miRNA highly enriched in the endothelium, plays a crucial role in endothelial proliferation, migration, and tube formation (15) . In a mouse model, the atherosclerotic lesion area in the miR-126 
Materials and Methods

Participants
The BioCycle Study was a prospective cohort of 12 healthy regularly menstruating female volunteers aged 23 to 26 years, recruited from the Guangzhou Medical University and followed up for 1 cycle. The Guangzhou Medical University Review Board approved the study, and all participants provided written informed consent. All participants were completely compliant with the study protocol. The study involved 3 clinic visits, including early follicular phase (days 5 to 7), ovulation phase (days 14 to 16), and midluteal phase (days 22 to 24 
Animal models and assessment of aortic atherosclerotic lesions
Six-week-old homozygous ApoE 2/2 female mice in the C57BL/6 background were obtained from The Jackson Laboratory (Bar Harbor, ME) and fed ad libitum an atherogenic diet containing 1.25% weight-to-weight ratio cholesterol. Female mice were anesthetized and bilaterally ovariectomized (OVX) at 8 weeks of age. After 1 week, pellets containing E2 (0.25 mg, 60-day release; Innovative Research of America, Sarasota, FL) were implanted subcutaneously. Mice were randomly divided into 7 groups (7 to 10 mice per group) as follows: sham, OVX, OVX plus E2, OVX plus miR-126-3p mimics, OVX plus E2 plus antagomir-126-3p, OVX plus control mimics, and OVX plus control antagomir. After 8 weeks of treatment, mice were euthanized and the hearts were embedded and serially sectioned. Sections with tricuspid valves were stained with Oil Red O and counterstained with hematoxylin. Images were captured and lesion areas were quantified with Leica QWin imaging software (Leica Microsystems, Wetzlar, Germany).
Cell cultures
HUVECs were cultured as previously described (16) . A complete description of the methods, including participants, cell culture and treatment, animal model, immunofluorescence staining, transfection experiments, luciferase assay, quantitative real-time polymerase chain reaction (PCR), western blot, cell proliferation, migration and tube formation assays, cell adhesion assay, and statistical analysis are presented in the Supplemental Materials and Methods. press.endocrine.org/journal/jcem
Results
The serum level of E2 was positively associated with miR-126-3p level As expected, hormones levels varied across the menstrual cycle (Supplemental Table 1 ). The relative level of serum miR-126-3p expression was increased during ovulation phase and midluteal phase compared with early follicular phase [ Fig. 1(A) ]. Moreover, the serum level of E2 was positively associated with serum miR-126-3p level [ Fig. 1(B) ].
E2 reduced aortic atherosclerotic lesion via miR-126
Aorta sinus plaque was extensively found in the OVX group compared with the sham group of ApoE 2/2 mice.
The size of plaque was significantly diminished in the OVX plus E2 group and this effect was significantly reversed when mice were injected with antagomir-126-3p (OVX plus E2 plus antagomir-126 group). The injection with miR-126-3p mimics alone (OVX plus miR-126) also reduced the lesion area. Additionally, negative control of antagomir and mimics had no effect on the size of plaque The staining of the histopathology slides of aortic roots showed that in OVX group, VCAM-1 and Spred1 were extensively found in plaque area and they were reduced in OVX plus E2 or miR-126-3p mimics alone groups. The antagomir-126-3p reversed the effect of E2 on the expressions of both proteins [ Fig. 2(B) ].
E2 increased miR-126 expression via Ets-1 in HUVECs
Treatment with E2 (1 nM to 1 mM) for 24 hours increased pri-miR-126 and mature miR-126-3p expression, and the maximal effect was achieved at the concentration of 10 nM [ Fig. 3(A) , Supplemental Fig. 2A ]. At this concentration, E2 increased miR-126-3p expression from 12 to 72 hours [ Fig. 3(B) ].
To identify the subtype of estrogen receptor (ER) involved, HUVECs were treated with selective ERa agonist PPT or ERb agonist DPN. It was found that PPT but not DPN mimicked the effect, which was inhibited by the pure ER antagonist ICI 182,780 (Supplemental Fig. 2B) .
Genome bioinformatics promoter analysis revealed that Sp1 and Ets-1 binding motifs are prevalent in miR-126 host EGLF7 gene (http://www.cbrc.jp/research/db/ TFSEARCH.htm). To identify their roles, we silenced these 2 transcription factors by using small interfering RNAs (siRNAs; Supplemental Fig. 2C ). E2 (10 nM) failed to increase miR-126-3p expression when Ets-1 was knocked down, whereas this effect was not altered by the silencing of Sp1 [ Fig. 3(C) ].
To examine the role of E2 on transcriptional activity of Ets-1, HUVECs were transiently transfected with an Ets-1 binding site-luciferase reporter plasmid. E2 (10 nM) or PPT (10 nM) significantly increased the transcriptional activity of Ets-1, which was inhibited by ICI 182,780 [ Fig. 3(D) ].
E2 increased Ets-1 protein expression via the c-Src/phosphatidylinositol 3-kinase/Akt pathway Different doses of E2 (1 nM to 1 mM) enhanced Ets-1 protein expression in HUVECs [ Fig. 4(A) ]. Moreover, E2 (10 nM) increased Ets-1 expression from 12 to 48 hours [ Fig. 4(B) ]. This effect was mimicked by PPT and was blocked by ICI 182,780 (Supplemental Fig. 2D ). E2-induced Ets-1 expression was inhibited by phosphatidylinositol 3-kinase (PI3K) inhibitor wortmannin (30 nM) or nonreceptor tyrosine kinase c-Src inhibitor PP2 (10 mM), while not altered by MAPK inhibitor PD98059 (5 mM) or G protein inhibitor pertussis toxin (100 ng/mL) [ Fig. 4(C) ].
When HUVECs were transfected with c-Src or Akt siRNA (Supplemental Fig. 2E ), E2 failed to increase Ets-1 protein and miR-126-3p expression [ Fig. 4(D) and 4(E) ]. Moreover, E2 could not induce Akt phosphorylation when c-Src was silenced, whereas it still increased c-Src press.endocrine.org/journal/jcemphosphorylation when Akt protein was knocked down [ Fig. 4(D) ].
E2 promoted HUVECs proliferation and tube formation via miR-126-3p/Spred1
To clarify the role of miR-126-3p in E2-regulated endothelial proliferation, migration, and tube formation, antagomir-126-3p was efficiently transfected into HUVECs (Supplemental Fig. 3A ). In agreement with our previous reports, E2 (10 nM) stimulated HUVECs proliferation, migration, and tube formation, which were largely inhibited by antagomir-126-3p (Supplemental Fig. 3B-D) .
Treatment with different doses of E2 (1 nM to 1 mM) at various time points decreased Spred1 protein expression [ Fig. 5(A) and 5(B) ]. Meanwhile, E2 did not reduce Spred1 mRNA level (Supplemental Fig. 4A ), and the antagomir-126-3p blocked E2 effect on Spred1 protein expression [ Fig. 5(C) ]. Overexpression of Spred1 (Supplemental Fig. 4B ) strongly inhibited the effects of E2 on 
E2 reduced monocyte adhesion into HUVECs via miR-126/VCAM-1
The challenge with lipopolysaccharide (LPS) greatly increased VCAM-1 expression in HUVECs, which was inhibited by E2 in a dose-and time-dependent manner [ Fig. 6(A) and 6(B) ]. Although E2 decreased the LPSinduced increase of VCAM-1 mRNA level (Supplemental Fig. 5A ), the antagomir126-3p still largely reversed the inhibitory effect of E2 on VCAM-1 expression [ Fig. 6(C) ]. As a result, LPS increased the number of monocytes adhering to HUVECs [ Fig. 6(D) , Supplemental Fig. 5B ]. E2 inhibited the LPS effect, which was reversed by antagomir126 [ Fig. 6(D) , Supplemental  Fig. 5 ].
Discussion
The major finding of the present study is the identification of miR-126 as the direct target of estrogen in human endothelial cells. Through an ERa-and Ets-1-dependent mechanism, E2 upregulates miR-126-3p expression and promotes endothelial proliferation, migration, and tube formation and inhibits monocyte adhesion, and thus it press.endocrine.org/journal/jcemmay provide a beneficial effect against the development of AS. miR-126-3p is highly enriched in the endothelium, and it retards the development of AS via its impacts on vascular endothelial functions. In this study, we found that serum concentrations of miR-126-3p in cycling women were higher in the ovulatory and luteal phases than in the follicular phase and it was positively correlated with E2 values. Moreover, in healthy postmenopausal women, the serum miR-126-3p was much lower than that in healthy young women (data not shown). These data suggested that E2 may regulate miR-126-3p expression in physiological status. Because miR-126-3p serves as a potential biomarker for early identification of cardiovascular diseases (17), the loss of miR-126-3p may also be the possible cause for increased incidence of cardiovascular disease in postmenopausal women. This concept is supported by our in vivo animal experiment data that the injection of miR-126-3p mimics attenuated the lesion area in ApoE 2/2 mice. More importantly, antagomir-126-3p partially reversed the E2 effect on lesion area, which implies that miR-126-3p plays an important role in estrogen's antiatherogenesis effect in vivo. Ets-1 is the well-known transcription factor driving miR-126 expression by the binding of the E-domain to the GGAA/T core element in the EGLF7 gene sequence (18) . In agreement with this, we found that Ets-1 is the key mediator. E2 increased Ets-1 transcriptional activity, which may be due to the increased phosphorylation of Ets-1. Meanwhile, we noticed that several Sp1 binding motifs exist in the miR-126 host EGLF7 gene. Sp1 is established downstream of ER signaling, and under certain circumstances Ets1/Sp1 bind cooperatively to DNA (19) . In this study, the silencing of Sp1 did not alter miR-126-3p expression, indicating that Sp1 is not indispensable for this E2-related effect.
We found that E2 increased Ets-1 protein expression in human endothelial cells, which is in line with a report on endothelial cells cocultured with tumor cells (20) . Currently, the mechanisms for the regulation of Ets-1 expression remain obscure. It was reported that different stimuli, such as tissue factor or vascular endothelial growth factor, increased Ets-1 expression or enhanced its transcriptional activity via the PI3K/Akt-or nuclear factor kB-dependent pathway in endothelial cells or tumor cells (21) (22) (23) . In agreement, our work indicated that Akt was crucial for E2-enhanced Ets-1/miR-126-3p expression. As the key regulator of cell proliferation, survival, and metabolism, Akt affects many gene transcriptions by activating a series of downstream transcription factors. However, in this study, the specific Akt downstream responsible for Ets-1 expression was undetermined and it needs to be further investigated.
We identified that Ets-1/miR-126-3p was the target modulated by Akt in vascular endothelial cells. Alternatively, miR-126 is capable of regulating PI3K/ Akt. For instance, in vascular endothelial cells, miR-126 overexpression enhanced PI3K/Akt activities (24) . From this point of view, a positive feedback loop between Akt and miR-126 may exist. In contrast, recent evidence indicated that miR-126 downregulated PI3K/Akt signaling in acute myeloid leukemia stem cells (25) . Therefore, the modulatory pattern between these molecules is complicated and different in a tissue-dependent fashion.
c-Src is the prototypical member of the Src family and miRNAs are the fine press.endocrine.org/journal/jcemtuners of c-Src signaling (26) . In this study, we found that E2 activated Akt via c-Src, and the silencing of c-Src reversed the E2 effect on miR-126-3p expression. Our results showed that long-term treatment with E2 increased the phosphorylation of tyrosine Y419 in the c-Src SH1 kinase domain, which is the key event associated with its catalytically active conformation (27) . It was reported that plasma membrane ERa interacts with c-Src and PI3K and can activate them rapidly (28) . Thus, E2 may affect miRNAs via c-Src in a nongenomic manner, and further studies should be done by using specific nongenomic activators such as estrogen dendrimer conjugate to test this possibility. Spred1 is a member of the sprouty-related protein with EHV-1 domain family. It inhibits mitogenic signaling induced by a wide range of different growth factors, cytokines, and chemokines through the suppression of the Ras-extracellular signal-regulated kinase pathway (29) . By repressing the expression of Spred1, miR-126-3p governs vascular integrity and angiogenesis and accelerates vascular endothelial repair (30, 31) . In this study, we reported that Spred1 is the new target protein of estrogen. E2 did not alter its mRNA level but decreased its protein expression, which was blocked by the antagomir-126-3p, suggesting that the regulation is dependent on the well-established miR-126-3p pathway. The overexpression of Spred1 partially blocked E2-enhanced endothelial cell proliferation, migration, and tube formation, indicating that Spred1 acts as a potent repressor for estrogen's vascular effects.
Similar to Spred1, VCAM-1 is another well-known target of miR-126-3p. It mediates leukocyte adhesion and transmigration on or through the endothelium. The blockade of VCAM-1 significantly reduced monocyte adhesion and diminished atherosclerotic lesions in a mouse model (32) . We have previously reported that E2 decreased VCAM-1 mRNA and protein expression via the inhibition of nuclear factor kB signaling in vascular endothelial cells (33) . Apart from that, in this study we further showed that E2 regulated VCAM-1 expression via miR-126, which manifests the integrated pattern of estrogen's actions on target protein from gene transcription to translation.
In conclusion, we found that E2 enhances endothelial miR-126-3p expression via Ets-1. Then, miR-126-3p binds to its targets Spred1 and VCAM-1 mRNA, leading to their degradation and the silencing of protein expression, and finally promoting endothelial proliferation, migration, and tube formation and inhibiting monocyte adhesion. These findings may provide a potential pathway that may account for estrogen's antiatherogenesis effect and hint at the possibility that the interference of miRNAs may represent an efficient avenue to reduce the risk of cardiovascular diseases in postmenopausal women.
